Loading...
Last update:  November 17, 2019
19:55 +1GMT

Allergenic Molecule  Hev b 6Homo sapiens  
Epidemiology from Literature
CohortYearCountryTestSubjectsPositive (%)Bibliography
1.5 - Atopic Dermatitis, Diagnosed2014Korea, Republic ofIgE254.00020140821, Choi JS
1.5 - Atopic Dermatitis, Diagnosed2013GermanyIgE1400.71020130111, Ott H
1.11 - Esophagitis, Diagnosed2013NetherlandsIgE761.30020131020, van Rhijn BD
1.11 - Esophagitis, Diagnosed2013SwitzerlandIgE355.71020130605, Simon D
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2013BrazilIgE1172.72020130429, Bueno de Sa A
6.2 - General Population (Adults)2012SwedenIgE3710.00020120528, Patelis A
5.3.1 - Source Exposed (Symptoms, IgE)2012BelgiumIgE994.04020110223, De Knop KJ
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2012FranceIgE9775.00020120706, Garnier L
1.2.1 - Asthma, Diagnosed (Adults)2012SwedenIgE961.04020120528, Patelis A
6.5 - Occupational Exposure2012South AfricaIgE8511.76020120404, Singh T
6.5 - Occupational Exposure2012South AfricaIgE857.06020120404, Singh T
10.1 - Normal Control2012BelgiumIgE270.00020110223, De Knop KJ
1.10 - Any allergy symptom, Diagnosed2010ItalyIgE164081.30020100301, Scala E
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2010Italy / Austria / Switzerland / NetherlandsIgE10129.70020101118, Bublin M
1.10 - Any allergy symptom, Diagnosed2010BelgiumIgE8610.46020101214, Gadisseur R
5.3.1 - Source Exposed (Symptoms, IgE)2010Austria / ItalyIgE5957.62020101124, Radauer C
5.3.1 - Source Exposed (Symptoms, IgE)2010GermanyIgE5269.23020100423, Ott H
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2010Italy / Austria / Switzerland / NetherlandsIgE4825.00020101118, Bublin M
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2009BelgiumIgE375.40520090826, Ebo DG
1.1 - Asymptomatic2009BelgiumIgE260.00020091121, Ebo DG
5.3.1 - Source Exposed (Symptoms, IgE)2009BelgiumIgE2281.82020091121, Ebo DG
3.2.1 - Source Sensitized (IgE)2009BelgiumIgE200.00020091121, Ebo DG
1.5 - Atopic Dermatitis, Diagnosed2009GermanyIgE2015.00020091005, Ott H
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2009JapanIgE14100.00020090520, Yagami A
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2009JapanSPT14100.00020090520, Yagami A
3.2.1 - Source Sensitized (IgE)2009ItalyIgE71.42020091030, Quercia O
5.3.1 - Source Exposed (Symptoms, IgE)2008PortugalIgE5100.00020080904, Rodrigues Alves R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2006SpainIgE2369.70020060324, Sanz ML
5.3.1 - Source Exposed (Symptoms, IgE)2005SpainIgE3154.800
5.7.3 - Source Exposed (Provocation Test - Skin Contact)2005FinlandSPT1586.700
5.2.1 - Source Exposed (Symptoms, SPT)2004SpainSPT6178.700
6.5 - Occupational Exposure2004MexicoSPT5016.000
3.1.2 - Source Sensitized - High Exposure (SPT)2003United StatesSPT6263.000
5.1.1 - Source Exposed (Symptoms)2003GermanyIgE5870.700
5.1.1 - Source Exposed (Symptoms)2000United StatesIgE4459.100
5.2.1 - Source Exposed (Symptoms, SPT)2000CanadaSPT2965.500
5.4.1 - Source Exposed (Symptoms, SPT, IgE)1998GermanyIgE11877.100
5.4.1 - Source Exposed (Symptoms, SPT, IgE)1998GermanyIgE7824.300
5.4.1 - Source Exposed (Symptoms, SPT, IgE)1998FinlandIgE4278.600
5.2.1 - Source Exposed (Symptoms, SPT)1996FinlandIgE4566.700
Developed by
Panservice